Drug-Coated Stent Versus Drug-Eluting Stent for One-month Dual-antiplatelet Therapy in Patients With Acute Coronary Syndrome: ONE-PASS Trial
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of all-cause mortality, any MI, or any revascularization) in a setting of 1-month dual-antiplatelet therapy (DAPT) strategy (1-month DAPT followed ticagrelor monotherapy) after acute coronary syndrome.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Age ≥19 years
• All subjects who are acceptable candidates for treatment with a drug-coated stent or drug-eluting stent because of acute coronary syndrome
• Provision of informed consent
Locations
Other Locations
Republic of Korea
Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
RECRUITING
Seoul
Contact Information
Primary
Chul-Min Ahn
drcello@yuhs.ac
+82-2-2228-8532
Backup
Sung-Jin Hong, MD, PhD
hongs@yuhs.ac
+82-2-2228-8452
Time Frame
Start Date: 2022-08-10
Estimated Completion Date: 2030-02-14
Participants
Target number of participants: 3520
Treatments
Experimental: DCS group
Drug-coated stent group
Active_comparator: DES group
Drug-eluting stent group
Authors
Related Therapeutic Areas
Sponsors
Leads: Yonsei University